Lucy A. Bartho

Lucy A. Bartho

Auto-generated profile, based on publicly available information

Lucy A. Bartho

Translational Obstetrics Group, The Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, 163 Studley Road, Heidelberg, 3084, Victoria, Australia; Mercy Perinatal, Mercy Hospital for Women, Victoria, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
JFJoshua J. Fisher
Joshua J. Fisher
LBLucy A. Bartho
Lucy A. Bartho
Tony PerkinsTony Perkins
Tony Perkins
OHOlivia Holland
Olivia Holland

1 September 2021 in Placenta
Verified
Journal Article
Closed access
LBLucy A. Bartho
Lucy A. Bartho
JOJessica L. O'CAllaghan
Jessica L. O'CAllaghan
JFJoshua J. Fisher
Joshua J. Fisher
JCJames S.M. Cuffe
James S.M. Cuffe
TKTu'UHevaha J. Kaitu'U-Lino
Tu'UHevaha J. Kaitu'U-Lino
Tony PerkinsTony Perkins
Tony Perkins

6 July 2023 in EBioMedicine
Verified
Journal Article
Open access
LBLucy A. Bartho
Lucy A. Bartho
EKEmerson Keenan
Emerson Keenan
SWSusan P. Walker
Susan P. Walker
TMTeresa M. MacDonald
Teresa M. MacDonald
BNBrunda Nijagal
Brunda Nijagal
TKTu'UHevaha J. Kaitu'U-Lino
Tu'UHevaha J. Kaitu'U-Lino
Lipids serve as multifunctional metabolites that have important implications for the pregnant mother and developing fetus. Abnormalities in lipids have emerged as potential risk factors for pregnancy diseases, such as preeclampsia and fetal growth restriction. The aim of this study was to assess the potential of lipid metabolites for detection of late-onset preeclampsia and fetal growth restriction. We used a case-cohort of 144 maternal plasma samples at 36 weeks’ gestation from patients before the diagnosis of late-onset preeclampsia (n = 22), delivery of a fetal growth restricted infant (n = 55, defined as <5th birthweight centile), gestation-matched controls (n = 72). We performed liquid chromatography-tandem mass spectrometry (LC-QQQ) -based targeted lipidomics to identify 421 lipids, and fitted logistic regression models for each lipid, correcting for maternal age, BMI, smoking, and gestational diabetes. Phosphatidylinositol 32:1 (AUC = 0.81) and cholesterol ester 17:1 (AUC = 0.71) best predicted the risk of developing preeclampsia or delivering a fetal growth restricted infant, respectively. Five times repeated five-fold cross validation demonstrated the lipids alone did not out-perform existing protein biomarkers, soluble tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) for the prediction of preeclampsia or fetal growth restriction. However, lipids combined with sFlt-1 and PlGF measurements improved disease prediction. This study successfully identified 421 lipids in maternal plasma collected at 36 weeks’ gestation from participants who later developed preeclampsia or delivered a fetal growth restricted infant. Our results suggest the predictive capacity of lipid measurements for gestational disorders holds the potential to improve non-invasive assessment of maternal and fetal health. This study was funded by a grant from 10.13039/501100000925 National Health and Medical Research Council .

9 July 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LBLucy A. Bartho
Lucy A. Bartho
DMDaniel R. McKeating
Daniel R. McKeating
SWSusan P. Walker
Susan P. Walker
BNBrunda Nijagal
Brunda Nijagal
TMTeresa M. MacDonald
Teresa M. MacDonald
TKTu’uHevaha J. Kaitu’u-Lino
Tu’uHevaha J. Kaitu’u-Lino
Metabolomics is the study of small molecules (metabolites), within cells, tissues and biofluids. Maternal metabolites can provide important insight into the health and development of both mother and fetus throughout pregnancy. This study assessed metabolic profiles in the maternal circulation prior to and at the time of diagnosis of preeclampsia and fetal growth restriction. Maternal plasma samples were collected from two independent cohorts: (1) Established disease cohort: 50 participants diagnosed with early-onset preeclampsia (< 34 weeks’ gestation), 14 with early-onset fetal growth restriction, and 25 gestation-matched controls. (2) Prospective cohort, collected at 36 weeks’ gestation before diagnosis: 17 participants later developed preeclampsia, 49 delivered infants with fetal growth restriction (birthweight < 5th centile), and 72 randomly selected controls. Metabolic evaluation was performed by Metabolomics Australia on the Agilent 6545 QTOF Mass Spectrometer. In the established disease cohort, 77 metabolites were altered in circulation from participants with preeclampsia – increased l-cysteine (3.73-fold), l-cystine (3.28-fold), l-acetylcarnitine (2.57-fold), and carnitine (1.53-fold) (p < 0.05). There were 53 metabolites dysregulated in participants who delivered a fetal growth restriction infant—including increased levulinic acid, citric acid (1.93-fold), and creatine (1.14-fold) (p < 0.05). In the prospective cohort, 30 metabolites were altered in participants who later developed preeclampsia at term – reduced glutaric acid (0.85-fold), porphobilinogen (0.77-fold) and amininohippuric acid (0.82-fold) (p < 0.05) was observed. There were 5 metabolites altered in participants who later delivered a fetal growth restriction infant – including reduced 3-methoxybenzenepropanoic acid (p < 0.05). Downstream pathway analysis revealed aminoacyl-tRNA biosynthesis to be most significantly altered in the established cohort in preeclampsia (13/48 hits, p < 0.001) and fetal growth restriction (7/48 hits, p < 0.001). The predictive cohort showed no significant pathway alterations. This study observed altered metabolites in maternal plasma collected before and after diagnosis of a preeclampsia or fetal growth restriction. While a significant number of metabolites were altered with established disease, few changes were observed in the predictive cohort. Thus, metabolites measured in this study may not be useful as predictors of preeclampsia or fetal growth restriction.

7 March 2023 in Endocrinology
Verified
Journal Article
Open access
PDF file
LBLucy A Bartho
Lucy A Bartho
MKManju Kandel
Manju Kandel
SWSusan P Walker
Susan P Walker
CCCatherine A Cluver
Catherine A Cluver
RHRoxanne Hastie
Roxanne Hastie
TKTu’uHevaha J Kaitu’u-Lino
Tu’uHevaha J Kaitu’u-Lino
Background Preeclampsia is a severe complication of pregnancy. Chemerin is an adipokine secreted from adipose tissue and highly expressed in placenta. This study evaluated the biomarker potential of circulating chemerin to predict preeclampsia. Methods Maternal plasma and placenta were collected from women with early onset preeclampsia (<34 weeks’); preeclampsia and eclampsia; or before preeclampsia diagnosis (36 weeks’). Human trophoblast stem cells were differentiated into syncytiotrophoblast or extravillous trophoblasts across 96 hours. Cells were cultured in 1% O2 (hypoxia) or 5% O2(normoxia). Chemerin was measured by ELISA and RARRES2 (gene coding chemerin) by RT-qPCR. Results Circulating chemerin was increased in 46 women with early onset preeclampsia (<34 weeks’) compared to 17 controls (P < 0.0006). Chemerin was increased in placenta from 43 women with early onset preeclampsia, compared to 24 controls (P < 0.0001). RARRES2 was reduced in placenta from 43 women with early onset preeclampsia versus 24 controls (P < 0.0001). Chemerin was increased in plasma from 26 women with established preeclampsia (P = 0.006), versus 15 controls. Circulating chemerin was increased in 23 women who later developed preeclampsia, versus 182 who did not (P = 3.23E-06). RARRES2 was reduced in syncytiotrophoblast (P = 0.005) or extravillous trophoblasts (P < 0.0001). Hypoxia increased RARRES2 expression in syncytiotrophoblast (P = 0.01), but not cytotrophoblast cells. Conclusions Circulating chemerin was elevated in women with early-onset preeclampsia, established preeclampsia, and preceding preeclampsia diagnosis of preeclampsia. RARRES2 was dysregulated in placenta complicated by preeclampsia and may be regulated through hypoxia. Chemerin may have potential as a biomarker for preeclampsia but would need to be combined with other biomarkers.

14 October 2022 in Frontiers in Physiology
Verified
Journal Article
Open access
MKManju Kandel
Manju Kandel
STStephen Tong
Stephen Tong
SWSusan P Walker
Susan P Walker
PCPing Cannon
Ping Cannon
TNTuong-Vi Nguyen
Tuong-Vi Nguyen
LBLucy A Bartho
Lucy A Bartho
Preeclampsia is a disease of pregnancy responsible for significant maternal and neonatal mortality. Galectin-3 is a β-Galactoside binding protein. This study aimed to characterise galectin-3 in women with preeclampsia and human trophoblast stem cells (hTSCs). Galectin-3 was measured in placental lysates and plasma collected from patients with early-onset preeclampsia (delivered <34 weeks’ gestation) and gestation matched controls. Placental galectin-3 protein was significantly reduced in 43 women with early-onset preeclampsia compared to 21 controls. mRNA expression of LGALS3 (galectin-3 encoding gene) was reduced in 29 women with early-onset preeclampsia, compared to 18 controls (p = 0.009). There was no significant difference in plasma galectin-3 protein in 46 women with early-onset preeclampsia compared to 20 controls. In a separate cohort of samples collected at 36 weeks’ gestation, circulating galectin-3 was not altered in 23 women who later developed preeclampsia, versus 182 who did not. In syncytialised hTSCs, hypoxia increased mRNA expression of LGALS3 (p = 0.01). Treatment with inflammatory cytokines (TNF-α and IL-6) had no effect on LGALS3 mRNA expression. However, TNF-α treatment caused an increase in mRNA expression of LGALS3BP (galectin-3 binding protein encoding gene) in hTSCs (p = 0.03). This study showed a reduction of galectin-3 in placenta from pregnancies complicated by early-onset preeclampsia. LGALS3 mRNA expression was dysregulated by hypoxia exposure in placental stem cells.